

# POLYPEPTIDE GROUP AG CHF0.01

ISIN: CH1110760852 WKN: 111076085

### Overview





Information about previous performance does not guarantee future performance. **Source:** FactSet


#### **Recent research**


on sector	on market						
Date		Headline	Download				
2024/09/27	80 88 87 88	Global Equity Ratings					
2024/09/11	80. 128 27 198	Global Equity Ratings					
2024/09/05	80.   68 87   188	Global Equity Ratings					
2024/08/12	80. 128 27 198	Global Equity Ratings					
2024/07/24	80.   160 80.   160	Global Equity Ratings	.≛.				



**GROUP AG CHF0.01** 

## **Details**





Information about previous performance does not guarantee future performance. **Source:** FactSet

Price data				
Ø price 5 days   Ø volume 5 days (pcs.)	- USD (-)			
Ø price 30 days   Ø volume 30 days (pcs.)	- USD (-)			
Ø price 100 days   Ø volume 100 days (pcs.)	- USD (-)			
Ø price 250 days   Ø volume 250 days (pcs.)	- USD (-)			
YTD High   date	- USD (-)			
YTD Low   date	- USD (-)			
52 Weeks High   date	- USD (-)			
52 Weeks Low   date	- USD (-)			

All listings for POLYPEPTIDE GROUP AG CHF0.01					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
SIX Swiss Exchange	2024/10/ 18	17:30	29.75 CHF	0.66	293
London Stock Exchange	2024/05/ 07	13:59	31.25 CHF	0.30	1
FINRA other OTC Issues	-	-	-	0.00	1



# Company profile

### **Company Logo**

### **Contact Details**

POLYPEPTIDE GROUP AG

\_ \_

Neuhofstrasse 24 - 6340 Baar

Telefon: +41-43-502-05-80

Fax: +

E-mail: info@polypeptide.com

### **PDF Downloads**

Company report: POLYPEPTIDE GROUP AG CHF0.01



Ł

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

	Members of Management Board			
	Juan-José Gonzalez	Chairman of Managing Board		
	Christina del Vecchio	Member of Executive Committee		
	Jens Fricke	Member of Executive Committee		
	Marc Augustin	Member of Executive Committee		
	Neil Thompson	Member of Executive Committee		
	Stéphane Varray	Member of Executive Committee		

Board of directors				
Beat In-Albon	Member of the administrative board			
Jane Salik	Member of the administrative board			
Patrick Aebischer	Member of the administrative board			
Philippe Weber	Member of the administrative board			
Erik Schropp	Member of the administrative board			
Peter Wilden	Chairman of the administrative boar			

